3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Breast Neoplasms
13
Neoplasm Metastasis
3
Neoplasms by Site
2
Neoplasms
2
Breast Diseases
2
Advanced Breast Cancer
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Skin Diseases
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Lymphoma, Follicular
1
Endometrial Neoplasms
1
ER+ HER2- Advanced Breast Cancer
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Interventions
Fulvestrant
13
Letrozole
6
Anastrozole
5
palbociclib
4
exemestane
3
Injections
3
Docetaxel
3
Paclitaxel
2
Goserelin
2
Dasatinib
2
Capecitabine
2
Alpelisib
2
AZD9833
2
vandetanib
1
ribociclib
1
irinotecan sucrosofate
1
entinostat
1
elacestrant
1
cediranib
1
abemaciclib
1
XMT-1522
1
Vinorelbine
1
Sirolimus
1
Ritonavir
1
Lead
1
Itraconazole
1
Immunotherapy, Adoptive
1
Everolimus
1
Decitabine
1
Combined Modality Therapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Advanced Breast Cancer
×
AZD9833
×
Clear all
NCT07427394
2026-05-28
SERENA-1b
AstraZeneca
Phase 2
Recruiting
24 enrolled
NCT06380751
2026-05-15
EvoPAR-BR01
AstraZeneca
Phase 3
Recruiting
500 enrolled